<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Teva-Pharmaceutical-Industries-Limited-Sponsored-ADR-US8816242098">Teva Pharmaceutical Industries Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/04/29/3283605/0/en/Teva-Delivers-Strong-Q1-2026-Results-Driven-by-Innovative-Portfolio-Growth-and-Disciplined-Execution.html">Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution</a>
    </div>

      <div class="me-0 me-md-5">
        For an accessible version of this Press Release, please visit www.tevapharm.com
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Teva-Pharmaceutical-Industries-Limited-Sponsored-ADR-US8816242098">Teva Pharmaceutical Industries Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/04/29/3283566/0/en/Teva-to-Acquire-Emalex-Biosciences-Adding-NDA-Ready-First-in-Class-Therapy-to-Neuroscience-Pipeline-and-Accelerating-Teva-s-Pivot-to-Growth-Strategy.html">Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva&#39;s Pivot to Growth Strategy</a>
    </div>

      <div class="me-0 me-md-5">
        PARSIPPANY, N.J. and CHICAGO, April 29, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Emalex Biosciences (“Emalex”) today announced a definitive agreement for Teva to acquire Emalex, including its lead asset, ecopipam. The positive Phase 3 data of ecopipam in children with Tourette syndrome demonstrated statisti...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Teva-Pharmaceutical-Industries-Limited-Sponsored-ADR-US8816242098">Teva Pharmaceutical Industries Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">The Motley Fool</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.fool.com/investing/2026/04/27/should-you-buy-teva-pharmaceutical-stock-now/">Teva Pharmaceutical&#39;s Turnaround Is Working. Here&#39;s When to Buy the Stock.</a>
    </div>

      <div class="me-0 me-md-5">
        Collectively, analysts tracking the stock expect declines in both revenue and profitability. The company continues to effect a major pivot in its business.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Teva-Pharmaceutical-Industries-Limited-Sponsored-ADR-US8816242098">Teva Pharmaceutical Industries Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">The Motley Fool</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.fool.com/investing/2026/04/18/x-catalysts-that-could-send-teva-stock-to-40-and-b/">3 Catalysts That Could Send Teva Stock to $40 and Beyond</a>
    </div>

      <div class="me-0 me-md-5">
        FDA approval of long-acting schizophrenia drug olanzapine could be Teva&#39;s biggest near-term catalyst. Teva&#39;s specialty drugs continue to gain momentum.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Teva-Pharmaceutical-Industries-Limited-Sponsored-ADR-US8816242098">Teva Pharmaceutical Industries Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/04/15/3274351/0/en/Teva-Launches-Home-Ground-Schizophrenia-Community-a-New-Online-Resource-Hub-for-People-Living-with-Schizophrenia-and-Their-Care-Partners.html">Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners</a>
    </div>

      <div class="me-0 me-md-5">
        PARSIPPANY, N.J. and TEL AVIV, Israel, April 15, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of Home Ground™ Schizophrenia Community, a new online platform designed to support people living with schizophrenia and their care partners with community-informed and experienced-based informati...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Teva-Pharmaceutical-Industries-Limited-Sponsored-ADR-US8816242098">Teva Pharmaceutical Industries Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/04/14/3273246/0/en/Community-Routes-Access-to-Mental-Health-Care-Provides-Continued-Funding-for-Mental-Health-Services-at-Free-Charitable-Clinics.html">Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free &amp; Charitable Clinics</a>
    </div>

      <div class="me-0 me-md-5">
        Supplemental funding helps 11 free &amp; charitable clinics and charitable pharmacies expand mental health care and reach more patients in underserved communities Supplemental funding helps 11 free &amp; charitable clinics and charitable pharmacies expand mental health care and reach more patients in underserved communities
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Teva-Pharmaceutical-Industries-Limited-Sponsored-ADR-US8816242098">Teva Pharmaceutical Industries Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/03/30/3264544/0/en/Teva-Gains-Biosimilar-Momentum-with-U-S-FDA-Approval-of-PONLIMSI-denosumab-adet-and-Dual-Filing-Acceptance-for-Biosimilar-Candidate-to-Xolair-omalizumab.html">Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)</a>
    </div>

      <div class="me-0 me-md-5">
        TEL AVIV, Israel and PARSIPPANY, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced three milestones in its biosimilar portfolio, demonstrating continued momentum in the advancement of its Pivot to Growth strategy. The United States (U.S.) Food and Drug Administration (FDA) has approved PONLIMSI (denosumab-adet) as a biosimilar to ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Teva-Pharmaceutical-Industries-Limited-Sponsored-ADR-US8816242098">Teva Pharmaceutical Industries Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/03/19/3259456/0/en/Teva-to-Host-Conference-Call-to-Discuss-First-Quarter-2026-Financial-Results-at-8-a-m-ET-on-April-29-2026.html">Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026</a>
    </div>

      <div class="me-0 me-md-5">
        TEL AVIV, Israel and PARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2026 financial results on Wednesday, April 29, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/Teva-Pharmaceutical-Industries-Limited-Sponsored-ADR-US8816242098/load_more?page=6">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>